(Q46491956)

22 December 2017

title

Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study (English)

1 reference

22 December 2017

1 reference

1 reference

3

Selma Ugurel

1 reference

22 December 2017

9

Dirk Schadendorf

1 reference

22 December 2017

1

Axel Hauschild

1 reference

22 December 2017

Reinhard Dummer

2

object named as

Reinhard Dummer

1 reference

22 December 2017

author name string

Katharina C Kaehler

4

1 reference

22 December 2017

Friederike Egberts

5

1 reference

22 December 2017

Wolfram Fink

6

1 reference

22 December 2017

Jeannine Both-Skalsky

7

1 reference

22 December 2017

Barbara Laetsch

8

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

22 December 2017

published in

Cancer

1 reference

22 December 2017

volume

113

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

page(s)

1404-1411

1 reference

22 December 2017

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23722

7 January 2021

Identifiers

DOI

10.1002/CNCR.23722

1 reference

22 December 2017

1 reference

22 December 2017